For medical professionals
Since the discovery of Avemar pulvis, the active ingredient of Avemar, more than 13 years of scientific studies have been completed to support its safety and effectiveness, including in vitro, in vivo and other clinical researches. Those years have provided consistent studies supporting Avemar’s ability to promote a better quality of life and maintain a healthy lifestyle in cancer patients undergoing clinical oncological treatments, including chemotherapy and radiotherapy. Avemar has been the subject of over 100 scientific studies and 33 PubMed publications. Avemar is also included in database of the Memorial Sloan-Kettering Cancer Center.
The Avemar Research Program has been funded by many government organizations such as: The Ministry of Education, Biotechnology and OTKA [Scientific Research Foundation] in Hungary, The Ministry of Health and the Ministry of Science and Technology in Spain, The UCLA, General Clinical Research Center and Clinical Nutrition Research Unit in the US, Inco-Copernicus from the European Union and The Scientific Program, NATO.
More than 100 published papers have reviewed the clinical and experimental results obtained with this extract and have also been published in prestigious journals. In vitro studies of cell cultures, animal studies and clinical trials with over 1200 people to date, have been undertaken in Hungary, Israel, Spain, Italy, Russia, the US and Australia to name a few. For more information please visit: http://research.avemar.com
Learn more about the:
- molecular targets of Avemar »
- the effects of Avemar on cancer cell metabolism »
- the effects of Avemar on the Immune system »